Epigenetic targets in B- and T-cell lymphomas: latest developments

Area of Science:

• Oncology
• Epigenetics
• Hematology

Background:

• Non-Hodgkin's lymphomas (NHLs) are diverse lymphoid malignancies with varied molecular and clinical features.
• While many NHLs respond to conventional treatments, relapsed/refractory cases have poor outcomes.
• Epigenetic dysregulations, including mutations in epigenetic enzymes, are prevalent in both B-cell and T-cell lymphomas.

Purpose of the Study:

• To summarize key epigenetic alterations in B- and T-cell NHLs.
• To review the development and clinical application of epigenetic-modifying agents (epidrugs) for NHLs.
• To explore future research directions and the role of bioinformatics in identifying new epigenetic targets.

Main Methods:

• Review of scientific literature on epigenetic alterations in NHLs.
• Analysis of clinical trial data for approved and investigational epidrugs.
• Discussion of bioinformatics approaches for target discovery.

Main Results:

• Epigenetic alterations are frequently observed in NHLs, impacting chromatin modifiers and DNA methyltransferases (DNMTs).
• Several classes of epidrugs, including DNMT, histone deacetylase (HDAC), and bromodomain and extra-terminal motif (BET) inhibitors, are under clinical investigation or approved.
• These agents show potential in treating specific NHL subtypes.

Conclusions:

• Epigenetic modifications represent a critical area for therapeutic intervention in NHL.
• Targeted epigenetic therapies, informed by deep sequencing and bioinformatics, hold promise for improving outcomes in relapsed/refractory NHL.
• Further research is needed to fully elucidate the role of epigenetics and optimize epidrug strategies.